United StatesIn 2026, the American Diabetes Association (ADA), once praised for its defense of scientific integrity, faces criticism over its handling of a controversial event at its annual meeting. The organization removed several physicians from the event after they distributed an opinion piece criticizing the Trump administration's cuts to science funding. The ADA cited its commitment to maintaining a nonpartisan environment, but over 200 members have since called for leadership changes, an investigation, and an apology. This situation echoes a past instance in 2015, when the ADA defended its journal Diabetes against a defamation lawsuit from Brazilian researcher Mario Saad, ultimately winning in court. The current controversy highlights tensions between scientific freedom and institutional policies.
Bias read (Center): The article presents both sides of the controversy—criticism of the ADA's actions and the organization's justification—and references legal and internal responses without overtly favoring one perspective. The framing remains balanced, focusing on the conflict between institutional policies and free言
